What Are Nootropic Peptides?
An introduction to peptides marketed for cognitive enhancement, including Semax, Selank, Dihexa and Cerebrolysin. What the cited evidence actually shows, in which species, and where it stops.
What Are Nootropic Peptides?
“Nootropic peptides” is a marketing category, not a pharmacological one. It groups together several unrelated compounds sold on the promise of better memory, focus or mental clarity. The compounds do not share a mechanism, a development history, or an evidence base.
This guide takes the five most commonly marketed examples and asks one question of each: what does the cited research actually show, and in what species?
The Compounds, and What the Cited Research Actually Tested
| Compound | What it is | Strongest evidence located | Species tested |
|---|---|---|---|
| Semax | Synthetic ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro tail | Increased transcription of neurotrophins and their receptors in ischaemic rat cortex | Rat |
| Selank | Synthetic heptapeptide, tuftsin analogue | One randomised trial as an add-on to phenazepam in anxiety disorders (70 patients total) | Human |
| Dihexa | Small-molecule angiotensin IV analogue | Rodent cognition studies pooled in a systematic review of non-human experiments | Rodent |
| Cerebrolysin | Porcine brain-derived mixture of low-molecular-weight peptides and amino acids | Cochrane review of 7 RCTs, 1,773 participants, in acute ischaemic stroke | Human |
| P021 | Ciliary neurotrophic factor (CNTF) small-molecule peptide mimetic | Prenatal-to-postnatal treatment in the Ts65Dn mouse model of Down syndrome | Mouse |
Semax: Rat Neurotrophin Data, Russian Clinical Use
The BDNF story attached to Semax comes from rodent work. A 2010 study in Cellular and Molecular Neurobiology gave Semax to rats after permanent middle cerebral artery occlusion and measured mRNA in the cortex at three time points. Semax raised transcription of Bdnf, TrkC and TrkA at 3 hours, and Nt-3 and Ngf at 24 hours. The authors also note that earlier experiments had shown induction of Bdnf, Ngf and TrkB in intact rat hippocampus.
Two things to hold onto:
- These are rat measurements of gene transcription, not human measurements of cognition.
- The same authors describe Semax as “successfully used for acute stroke therapy”. That is their description of clinical practice, not a Western regulatory approval, and the abstract names no country.
Of 51 PubMed records indexed under semax AND humans[mesh] on 17 August 2026, 40 carry a Russian affiliation or country field (26 by journal country, 20 by author affiliation, 40 as a union). The human literature is real, and it is heavily concentrated in one country’s research base.
No Semax study is registered on ClinicalTrials.gov.
Selank: One Add-On Trial, Not a Cognitive Enhancer Trial
Selank has human randomised data, which is more than most compounds in this category can claim. The design matters, though.
The trial compared phenazepam monotherapy (30 patients) against phenazepam plus Selank (40 patients) in anxiety-phobic, hypochondriac and somatoform disorders. Outcomes were assessed with HDRS, CGI, the Spielberger scale, the UKU side-effect scale, Stroop and verbal fluency tests, and SF-36.
What the authors reported: the phenazepam effect on HDRS arrived earlier when Selank was added, and several phenazepam side effects — including attention and memory impairment, sedation and asthenia — were less pronounced in the combination group.
What that is not: evidence that Selank enhances cognition in healthy people. The comparator was a benzodiazepine, not placebo; the population had diagnosed anxiety disorders; and the cognitive readouts were measuring the offset of a sedative’s side effects.
No Selank study appears in ClinicalTrials.gov. An intervention search returns two records, both transcranial-stimulation trials unrelated to the peptide.
Dihexa: Animal Data, and the Route Matters
Dihexa was synthesised in an academic laboratory pursuing angiotensin IV analogues for Alzheimer’s and Parkinson’s disease. That group’s own review describes the compound as metabolically stable, blood-brain-barrier penetrant, and proposed to act through the hepatocyte growth factor / c-Met receptor system — while also noting that the identity of the “AT4 receptor” the field is targeting remains contested.
A 2018 systematic review in Neuroscience and Biobehavioral Reviews pooled the angiotensin IV literature and was explicit about its scope: experimental, non-human studies only. Of 450 articles screened, 32 met inclusion criteria. In models of cognitive deficit, eight of nine studies found Ang IV and its analogues — Dihexa among them — improved spatial working memory or passive avoidance performance.
The review adds a detail that rarely survives into marketing copy: these peptides appeared most effective when given intracerebroventricularly, that is, injected directly into the brain’s ventricles, close to the time of learning or testing.
No Dihexa study is registered on ClinicalTrials.gov, and no human trial appears in the systematic review’s scope.
Cerebrolysin: The One With Real Trial Data, and It Is Not Encouraging
Cerebrolysin is the outlier: 42 studies are registered on ClinicalTrials.gov, and a Cochrane review has assessed it repeatedly since 2010.
The 2023 update included 7 randomised controlled trials totalling 1,773 participants in acute ischaemic stroke. Its conclusions, at moderate certainty:
- Probably no beneficial effect on preventing all-cause death.
- Probably no beneficial effect on the total number of people with serious adverse events.
- A potential increase in non-fatal serious adverse events.
The review also documents why weaker studies can look better than they are: risk of bias for selective outcome reporting was judged unclear across all included studies, allocation concealment was unclear in six of seven, and the manufacturer supported three of the multicentre studies.
This is what a well-studied compound in this category looks like. More evidence did not produce a stronger claim; it produced a weaker one.
P021: Mouse Data
P021 is a small-molecule peptide mimetic of ciliary neurotrophic factor. The frequently cited result is a 2017 Scientific Reports study in the Ts65Dn mouse model of Down syndrome, where prenatal-to-early-postnatal treatment rescued developmental delay and hippocampus-dependent memory deficits.
That is a mouse study, in a genetic disease model, with treatment starting before birth. It is not a finding about cognition in adults.
Regulatory Status
Searches of Drugs@FDA and the FDA drug-label database through the openFDA API on 17 August 2026 returned no approved product and no label on file for semax, selank, dihexa or cerebrolysin. A control search for semaglutide in the same session returned an approved product, so the null results reflect the database, not a failed query.
How to Read Claims in This Category
Four checks separate a real finding from a repackaged one:
- Species. Rat transcription data and mouse behavioural rescue are not human cognition results.
- Route. “Effective in animals” often means injected into the brain’s ventricles, not taken by any route a person would use.
- Comparator. The Selank trial compared a combination against a benzodiazepine, not against placebo.
- Direction of travel. Cerebrolysin accumulated the most trial data of any compound here, and the pooled result moved toward no benefit and a possible increase in non-fatal serious adverse events.
The Bottom Line
Of the five compounds most often sold as nootropic peptides, four have no registered clinical trial at all — though one of those four, selank, does have a published add-on trial in a clinical population — and the one with substantial randomised data failed to show benefit in a Cochrane review. An openFDA label and Drugs@FDA search on 17 August 2026 returned no approved product and no label for any of the five, searching both “P021” and “peptide 021” for the fifth.
This guide is for educational purposes only and is not medical advice. None of the compounds discussed is approved for cognitive enhancement.
Sources & Citations
- 2
- 5
- 7trialClinicalTrials.gov intervention search - Dihexa 0 studies, Semax 0 studies, Selank 0 matching studies, Cerebrolysin 42 studies (checked 2026-08-17)
ctgov-nootropic-peptide-registry-search
- 8regulatoryDrugs@FDA / openFDA drug label search - no approved product and no label on file for semax, selank, dihexa or cerebrolysin (checked 2026-08-17)
fda-nootropic-peptide-search
Disclaimer: This article is for educational purposes only and does not constitute medical advice. The information presented is based on current research but should not be used for diagnosis, treatment, or prevention of any disease. Always consult a qualified healthcare provider before making health decisions.